Immune checkpoint antibody drugs have opened up a new era in the field of tumor treatment since the 20th century. In 2021, the global market share of antitumor monoclonal antibody drugs has reached 62 billion US dollars. In recent years, domestic enterprises have also accelerated their development in this field. However, a big gap still exists between these enterprises and international pharmaceutical giants. In this context, it is of vital significance to fully grasp the international research and development trends and the panorama of the R&D pipeline. The research topics of core articles in this research field in the past 10 years were analyzed, and the development trend of the field was revealed through the evolution of the research topics. Seven active research directions were identified. In-depth analysis of specific research directions was carried out through further data mining from professional databases and institutional websites. Comprehensive analysis indicated that three directions including the efficacy and safety surveillance of marketed antibody drugs and drug combination, new antibody drugs such as bispecific antibodies and antibody-drug conjugates, and new targets represented by 4-1BB have been the research hotspots and focuses in recent years. Adverse event monitoring of marketed drugs should be strengthened, and efforts should be stepped up to support the research and development of new antibody drugs.

immunotherapy  /  monoclonal antibody  /  antineoplastic agents  /  bispecific antibody  /  antibody-drug conjugate